NanoViricides, Inc. (NNVC)

USD 0.99

(-4.81%)

Long Term Debt Summary of NanoViricides, Inc.

  • NanoViricides, Inc.'s latest annual long term debt in 2024 was - USD , down 0.0% from previous year.
  • NanoViricides, Inc.'s latest quarterly long term debt in 2024 Q4 was - USD , down 0.0% from previous quarter.
  • NanoViricides, Inc. reported annual long term debt of - USD in 2023, down 0.0% from previous year.
  • NanoViricides, Inc. reported annual long term debt of - USD in 2022, down 0.0% from previous year.
  • NanoViricides, Inc. reported quarterly long term debt of - USD for 2024 Q4, down 0.0% from previous quarter.
  • NanoViricides, Inc. reported quarterly long term debt of - USD for 2024 Q3, down 0.0% from previous quarter.

Annual Long Term Debt Chart of NanoViricides, Inc. (2024 - 2005)

Historical Annual Long Term Debt of NanoViricides, Inc. (2024 - 2005)

Year Long Term Debt Long Term Debt Growth
2024 - USD 0.0%
2023 - USD 0.0%
2022 - USD 0.0%
2021 - USD 0.0%
2020 - USD 0.0%
2019 - USD 0.0%
2018 - USD 0.0%
2017 - USD -100.0%
2016 3.13 Million USD -56.36%
2015 7.18 Million USD -20.54%
2014 9.03 Million USD 160.59%
2013 3.46 Million USD 0.0%
2012 - USD 0.0%
2011 - USD 0.0%
2010 - USD 0.0%
2009 - USD 0.0%
2008 - USD 0.0%
2007 - USD -100.0%
2006 917.08 Thousand USD 0.0%
2005 - USD 0.0%

Peer Long Term Debt Comparison of NanoViricides, Inc.

Name Long Term Debt Long Term Debt Difference
AIM ImmunoTech Inc. 495 Thousand USD 100.0%
Ampio Pharmaceuticals, Inc. - USD NaN%
Armata Pharmaceuticals, Inc. 82.3 Million USD 100.0%
Actinium Pharmaceuticals, Inc. 1.57 Million USD 100.0%
Azitra, Inc. 563.69 Thousand USD 100.0%
Can-Fite BioPharma Ltd. 13 Thousand USD 100.0%
Chromocell Therapeutics Corporation - USD NaN%
Calidi Biotherapeutics, Inc. 2.06 Million USD 100.0%
CEL-SCI Corporation 11.6 Million USD 100.0%
iBio, Inc. 3.5 Million USD 100.0%
Lineage Cell Therapeutics, Inc. 2.07 Million USD 100.0%
MAIA Biotechnology, Inc. - USD NaN%
Matinas BioPharma Holdings, Inc. 2.89 Million USD 100.0%
Navidea Biopharmaceuticals, Inc. 1.87 Million USD 100.0%
NovaBay Pharmaceuticals, Inc. 1.1 Million USD 100.0%
Oragenics, Inc. - USD NaN%
BiomX Inc. 5.4 Million USD 100.0%
BiomX Inc. 5.4 Million USD 100.0%
Protalix BioTherapeutics, Inc. 4.62 Million USD 100.0%
Palatin Technologies, Inc. 163.78 Thousand USD 100.0%
Scorpius Holdings, Inc. 12.61 Million USD 100.0%
Theriva Biologics, Inc. 162 Thousand USD 100.0%